Comparison of four different regimens against Helicobacter pylori as a first‐line treatment: A prospective, cross‐sectional, comparative, open trial in Chinese children

Helicobacter ◽  
2020 ◽  
Vol 25 (2) ◽  
Author(s):  
Ying Zhou ◽  
Ziqing Ye ◽  
Yuhuan Wang ◽  
Ye Zhang ◽  
Zifei Tang ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Open Trial ◽  
Chinese Children ◽  
Line Treatment ◽  
First Line ◽  
Cross Sectional ◽  
First Line Treatment

Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment forHelicobacter Pyloriinfection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial

Helicobacter ◽  
2018 ◽  
Vol 24 (1) ◽  
pp. e12546 ◽  
Author(s):  
Fernando Macías-García ◽  
Iria Bastón-Rey ◽  
Daniel de la Iglesia-García ◽  
Cristina Calviño-Suárez ◽  
Laura Nieto-García ◽  
...  
Keyword(s):  
High Resistance ◽  
Open Trial ◽  
Line Treatment ◽  
First Line ◽  
Cross Sectional ◽  
Quadruple Therapy ◽  
First Line Treatment

scholarly journals Efficacy of Bismuth-Containing Quadruple Therapy as First-line Treatment for Helicobacter pylori Infection

2012 ◽  
Vol 2 (2) ◽  
pp. 90-93
Author(s):  
Metin Küçükazman ◽  
Ayse Kefeli ◽  
Sebahat Basyigit ◽  
Abdullah Özgür Yeniova ◽  
Yasar Nazligül ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
First Line ◽  
Quadruple Therapy ◽  
First Line Treatment

scholarly journals Efficacy of Two-Week Therapy with Doxycycline-Based Quadruple Versus Levofloxacin Concomitant for Helicobacter Pylori Infection: A Prospective Single-Center Randomized Controlled Trial.

2021 ◽  
Author(s):  
Marouf Alhalabi ◽  
Waleed Alassi ◽  
Kamal Alaa Eddin ◽  
Khaled Cheha
Keyword(s):  
Helicobacter Pylori ◽  
Odds Ratio ◽  
Controlled Trial ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
First Line ◽  
Open Label ◽  
Randomized Controlled ◽  
First Line Treatment

Abstract Background: Antibiotic-resistant reduces the efficacy of conventional triple therapy for Helicobacter Pylori infections worldwide, lead to varying treatment protocols according to locations. This was an open‑label randomized controlled trial. We used two protocols, doxycycline-based quadruple and concomitant levofloxacin regimens. The aim was to compare the eradication rates of previous protocols as empirical first-line treatment to cure Helicobacter Pylori infection in intention-to-treat (ITT) and per-protocol analyses (PPA) in Syrian population.Settings and Design: an open‑label parallel randomized controlled trial.Methods: We randomly assigned seventy-eight naïve who tested positive for Helicobacter Pylori gastric infection, with a 1:1 ratio to (D-group ) which receive (bismuth subsalicylate 524 mg four times daily, doxycycline 100 mg, tinidazole 500 mg, and esomeprazole 20 mg, each twice per day for two weeks), or (L-group) which receive (levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each twice per day for two weeks). We confirmed Helicobacter Pylori eradication by stool antigen test at eight weeks. Results: Thirty-nine patients were allocated in each group. In the D-group, thirty-eight patients completed the follow-up, thirty patients were cured. While in the L-group, thirty-nine completed the follow-up, thirty-two patients were cured. According to ITT, the eradication rates were 76.92%, and 82.05%, for the D-group and L-group respectively. Odds ratio with 95% confidence interval was 1.371 [0.454-4.146]. According to PPA, the eradication rates were 78.9 %, and 82.05% for the D-group and L-group respectively. The odds ratio with 95% confidence interval was 1.219 [0.394-3.774]. We didn’t report serious adverse effects. Conclusions: The eradication rates in both therapy regimes were fair. Further researches are required to identify the optimum first-line treatment for Helicobacter-Pylori Infection in the Syrian population.Trial registration: We register this study as a standard randomized clinical trial (Clinicaltrial.gov, identifier‑NCT04348786, date:29-January-2020, https://clinicaltrials.gov/ct2/show/NCT04348786).

Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection

2015 ◽  
Vol 30 (7) ◽  
pp. 1134-1139 ◽  
Author(s):  
Tiing Leong Ang ◽  
Kwong Ming Fock ◽  
Mingjun Song ◽  
Daphne Ang ◽  
Andrew Boon Eu Kwek ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Sequential Therapy ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
Concomitant Therapy ◽  
First Line ◽  
First Line Treatment

Tu1295 - Systematic Review and Meta-Analysis: Concomitant Therapy Versus Triple Therapy for the First-Line Treatment of Helicobacter Pylori Infection

2018 ◽  
Vol 154 (6) ◽  
pp. S-926
Author(s):  
Jyh-Ming Liou ◽  
Mei-Jyh Chen ◽  
Chieh-Chang Chen ◽  
Jaw-Town Lin ◽  
Ming-Shiang Wu
Keyword(s):  
Systematic Review ◽  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Meta Analysis ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
Concomitant Therapy ◽  
First Line ◽  
First Line Treatment

scholarly journals Su1283 – Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy in First-Line Treatment of Helicobacter Pylori Infection: A Nationwide Randomized Trial in Korea

2019 ◽  
Vol 156 (6) ◽  
pp. S-529
Author(s):  
Jae G. Kim ◽  
Jae J. Kim ◽  
Yong Chan Lee ◽  
Il Ju Choi ◽  
Soon Man Yoon ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Randomized Trial ◽  
Triple Therapy ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

978 Standard Clarithromycin-Based Triple Therapy Is Superior to Levofloxacin-Based Triple Therapy As First-Line Treatment for Helicobacter pylori Eradication in a Chinese Population

2009 ◽  
Vol 136 (5) ◽  
pp. A-150
Author(s):  
Ivan F. Hung ◽  
Pierre Chan ◽  
Axel Hsu ◽  
David But ◽  
Walter Wai Kay Seto ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Chinese Population ◽  
Line Treatment ◽  
First Line ◽  
Helicobacter Pylori Eradication ◽  
First Line Treatment

10-day triple therapy with esomeprazole 40mg/12h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection

2016 ◽  
Vol 39 (9) ◽  
pp. 584-589
Author(s):  
Ana Campillo ◽  
Edurne Amorena ◽  
Miriam Ostiz ◽  
Marcos Kutz ◽  
Matilde LaIglesia
Keyword(s):  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Helicobacter Pylori Infection ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document